|
1
|
Constantinescu R, Elm J, Auinger P, Sharma
S, Augustine EF, Khadim L and Kieburtz K: NET-PDInvestigators:
Malignant melanoma in early-treated Parkinson's disease: The NET-PD
trial. Mov Disord. 29:263–265. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hiniker SM, Reddy SA, Maecker HT,
Subrahmanyam PB, Rosenberg-Hasson Y, Swetter SM, Saha S, Shura L
and Knox SJ: A prospective clinical trial combining radiation
therapy with systemic immunotherapy in metastatic melanoma. Int J
Radiat Oncol Biol Phys. 96:578–588. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hansson J, Aamdal S, Bastholt L, Brandberg
Y, Hernberg M, Nilsson B, Stierner U and von der Maase H; Nordic
Melanoma Cooperative Group, : Two different durations of adjuvant
therapy with intermediate-dose interferon alfa-2b in patients with
high-risk melanoma (Nordic IFN trial): A randomised phase 3 trial.
Lancet Oncol. 12:144–152. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Escudier B, Lassau N, Angevin E, Soria JC,
Chami L, Lamuraglia M, Zafarana E, Landreau V, Schwartz B, Brendel
E, et al: Phase I trial of sorafenib in combination with IFN
alpha-2a in patients with unresectable and/or metastatic renal cell
carcinoma or malignant melanoma. Clin Cancer Res. 13:1801–1809.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tang L, Zhang W, Su B and Yu B: Long
noncoding RNA HOTAIR is associated with motility, invasion, and
metastatic potential of metastatic melanoma. Biomed Res Int.
2013:2510982013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yan R, Cao J, Song C, Chen Y, Wu Z, Wang K
and Dai L: Polymorphisms in lncRNA HOTAIR and susceptibility to
breast cancer in a Chinese population. Cancer Epidemiol.
39:978–985. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chang CY, Chen PH, Lu SC, Hsieh MC, Lin
CW, Lee HM, Jawan B and Kao YH: Propofol-enhanced autophagy
increases motility and angiogenic capacity of cultured human
umbilical vascular endothelial cells. Life Sci. 142:49–59. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Glen JB, Hunter SC, Blackburn TP and Wood
P: Interaction studies and other investigations of the pharmacology
of propofol (‘Diprivan’). Postgrad Med J. 61 Suppl 3:S7–S14.
1985.
|
|
9
|
Goudra BG, Singh PM, Gouda G, Borle A,
Gouda D, Dravida A and Chandrasekhara V: Safety of non-anesthesia
provider-administered propofol (NAAP) sedation in advanced
gastrointestinal endoscopic procedures: Comparative meta-analysis
of pooled results. Dig Dis Sci. 60:2612–2627. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Orsini J, Nadkarni A, Chen J and Cohen N:
Propofol infusion syndrome: Case report and literature review. Am J
Health Syst Pharm. 66:908–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Habre C, Tramèr MR, Pöpping DM and Elia N:
Ability of a meta-analysis to prevent redundant research:
Systematic review of studies on pain from propofol injection. BMJ.
348:g52192014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Braz MG, Braz LG, Mazoti MA, Pinotti MF,
Pardini MI, Braz JR and Salvadori DM: Lower levels of oxidative DNA
damage and apoptosis in lymphocytes from patients undergoing
surgery with propofol anesthesia. Environ Mol Mutagen. 53:70–77.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang Q, Li J, Zhu H, Li P, Zou Z and Xiao
Y: Hmgb1-IL-23-IL-17-IL-6-Stat3 axis promotes tumor growth in
murine models of melanoma. Mediators Inflamm. 2013:7138592013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Y, Yuan J, Yang Q, Cao W, Zhou X, Xie
Y, Tu H, Zhang Y and Wang S: Immunoliposome co-delivery of bufalin
and anti-CD40 antibody adjuvant induces synergetic therapeutic
efficacy against melanoma. Int J Nanomedicine. 9:5683–5700.
2014.PubMed/NCBI
|
|
15
|
Guo J, Zhu J, Sheng X, Wang X, Qu L, Han
Y, Liu Y, Zhang H, Huo L, Zhang S, et al: Intratumoral injection of
dendritic cells in combination with local hyperthermia induces
systemic antitumor effect in patients with advanced melanoma. Int J
Cancer. 120:2418–2425. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen LG, Chang WL, Lee CJ, Lee LT, Shih CM
and Wang CC: Melanogenesis inhibition by gallotannins from Chinese
galls in B16 mouse melanoma cells. Biol Pharm Bull. 32:1447–1452.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang D, Zhou XH, Zhang J, Zhou YX, Ying
J, Wu GQ and Qian JH: Propofol promotes cell apoptosis via
inhibiting HOTAIR mediated mTOR pathway in cervical cancer. Biochem
Biophys Res Commun. 468:561–567. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lv XB, Lian GY, Wang HR, Song E, Yao H and
Wang MH: Long noncoding RNA HOTAIR is a prognostic marker for
esophageal squamous cell carcinoma progression and survival. PLoS
One. 8:e635162013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ding C, Cheng S, Yang Z, Lv Z, Xiao H, Du
C, Peng C, Xie H, Zhou L, Wu J and Zheng S: Long non-coding RNA
HOTAIR promotes cell migration and invasion via down-regulation of
RNA binding motif protein 38 in hepatocellular carcinoma cells. Int
J Mol Sci. 15:4060–4076. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang Z, Zhou L, Wu LM, Lai MC, Xie HY,
Zhang F and Zheng SS: Overexpression of long non-coding RNA HOTAIR
predicts tumor recurrence in hepatocellular carcinoma patients
following liver transplantation. Ann Surg Oncol. 18:1243–1250.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong M, Yang G, Liu H, Liu X, Lin S, Sun D
and Wang Y: Aged black garlic extract inhibits HT29 colon cancer
cell growth via the PI3K/Akt signaling pathway. Biomed Rep.
2:250–254. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mediani L, Gibellini F, Bertacchini J,
Frasson C, Bosco R, Accordi B, Basso G, Bonora M, Calabrò ML,
Mattiolo A, et al: Reversal of the glycolytic phenotype of primary
effusion lymphoma cells by combined targeting of cellular
metabolism and PI3K/Akt/mTOR signaling. Oncotarget. 7:5521–5537.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ochi E, Ishii N and Nakazato K: Time
course change of IGF1/Akt/mTOR/p70s6k pathway activation in rat
gastrocnemius muscle during repeated bouts of eccentric exercise. J
Sports Sci Med. 9:170–175. 2010.PubMed/NCBI
|
|
24
|
Li J, Li X, Xu W, Wang S, Hu Z, Zhang Q,
Deng X, Wang J, Zhang J and Guo C: Antifibrotic effects of luteolin
on hepatic stellate cells and liver fibrosis by targeting
AKT/mTOR/p70S6K and TGFbeta/Smad signalling pathways. Liver Int.
35:1222–1233. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pratheeshkumar P, Budhraja A, Son YO, Wang
X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al:
Quercetin inhibits angiogenesis mediated human prostate tumor
growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling
pathways. PLoS One. 7:e475162012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saraswati S, Kumar S and Alhaider AA:
α-santalol inhibits the angiogenesis and growth of human prostate
tumor growth by targeting vascular endothelial growth factor
receptor 2-mediated AKT/mTOR/P70S6K signaling pathway. Mol Cancer.
12:1472013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li SY, Fang CX, Aberle NS II, Ren BH,
Ceylan-Isik AF and Ren J: Inhibition of PI-3 kinase/Akt/mTOR, but
not calcineurin signaling, reverses insulin-like growth factor
I-induced protection against glucose toxicity in cardiomyocyte
contractile function. J Endocrinol. 186:491–503. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang L, Wang H, Xu J, Zhu J and Ding K:
Inhibition of cathepsin S induces autophagy and apoptosis in human
glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K
and JNK signaling pathways. Toxicol Lett. 228:248–259. 2014.
View Article : Google Scholar : PubMed/NCBI
|
